-
Company Insights
New![]()
Innovation and Patenting activity of Choice Hotels International Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Choice Hotels International Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Sector Analysis
New![]()
United Kingdom (UK) Home Personal Care Electricals Market Trends, Analysis, Consumer Dynamics and Spending Habits
The UK: Home Category Data, The Consumer - Personal care electircals 2023 report offers a comprehensive insight into consumer attitudes in the UK personal care electricals market. The report focuses on six key subcategories: overall personal care electricals, shavers, hairdryers, electric toothbrushes, hair styling, and beauty tools. Consumer data is based on our 2023 UK personal care electricals survey, using a panel of 2,000 nationally representative consumers.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene Nanivacirepvec in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene Nanivacirepvec in Endometrial Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for the...
-
Product Insights
New![]()
Windpark Greenport
Windpark Greenport is an Onshore Wind project located in Limburg, Netherlands. The project is owned and developed by Green Choice; Windunie. The project is currently partially active. Empower your strategies with our Windpark Greenport report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene nanivacirepvec in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene nanivacirepvec in Peritoneal Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene nanivacirepvec in Fallopian Tube Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene nanivacirepvec in Fallopian Tube Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene nanivacirepvec in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene nanivacirepvec in Ovarian Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene Nanivacirepvec in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene Nanivacirepvec in Solid Tumor Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene Nanivacirepvec in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene Nanivacirepvec in Non-Small Cell Lung Cancer Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olvimulogene Nanivacirepvec in Epithelial Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Olvimulogene Nanivacirepvec in Epithelial Tumor Drug Details: Olvimulogene nanivacirepvec (GL-ONC1) is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.